Porton Advanced Introduces MaxCyte’s ExPERT GTx Flow Electroporation System

• Porton Advanced has introduced the MaxCyte ExPERT GTx Flow Electroporation instrument to its cell therapy platform in China.

• This move makes Porton Advanced the first cell therapy CDMO in China to utilize this clinical-grade flow electroporation system.

Porton Advanced has strengthened its position in the cell therapy market by introducing the MaxCyte cGMP-grade ExPERT GTx Flow Electroporation instrument to its platform in China. This marks a significant advancement as Porton Advanced becomes the first cell therapy Contract Development and Manufacturing Organization (CDMO) in China to adopt this clinical-grade flow electroporation system.

The MaxCyte ExPERT GTx is renowned for its exceptional performance in achieving high transfection efficiency and maintaining cell viability. This capability is crucial for handling flexible transfection volumes and supporting the entire cell therapy process—from research and process development to clinical stages and cGMP production. It also scales up seamlessly for large-volume preparations, enhancing Porton Advanced’s capacity to meet diverse production needs.

Porton Advanced’s comprehensive cell therapy process equipment supports various cell types, including cell banking, autologous, and allogeneic cell therapy production. The introduction of the MaxCyte technology platform further augments its capabilities in non-viral electroporation for process development and clinical production. Already, Porton Advanced has leveraged MaxCyte’s systems to support multiple cell therapy projects, spanning from Investigator-Initiated Trials (IIT) and Investigational New Drug (IND) applications to clinical trials.

Porton Advanced emphasized collaboration with MaxCyte’s technical and compliance teams. This collaboration aims to accelerate the translation of gene and cell therapy drugs from laboratories to clinics and ultimately to the market. By integrating the MaxCyte ExPERT GTx and other electroporation technologies, Porton Advanced aims to empower the development and production of advanced therapies, reinforcing its commitment to advancing cell therapy solutions.